Knownwell, an in-person and virtual weight management company, raised a $20 million Series A to expand out of the Northeast, CEO Brooke Boyarsky Pratt tells Axios.
Why it matters: GLP-1 agonists are expensive, in short supply and not right for every patient, creating an opening for more holistic obesity management providers like Knownwell.
